Earnings ·
Bausch Health reports Q3 EPS of $1.15, raises full-year guidance and authorizes $50M buyback
BHCBausch Health Companies Inc.
Bausch Health Companies Inc. reported third-quarter consolidated revenues of $2.94 billion, a 10% increase from the prior year period. GAAP net income attributable to Bausch Health was $436 million, or $1.15 per diluted share, compared to $0.48 in the previous year. Adjusted earnings per diluted share rose 53% to $1.77, and consolidated adjusted EBITDA increased 32% to $1,305 million. The company raised its full-year 2026 revenue guidance to a range of $10.975 billion to $11.175 billion and adjusted EBITDA guidance to $4.315 billion to $4.415 billion. Additionally, the board authorized a $50 million share repurchase program intended to offset anticipated management equity vesting dilution in 2027. Bausch Health is a global diversified pharmaceutical company developing and marketing products in gastroenterology, hepatology, neuroscience, dermatology, and eye health.